1. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.
- Author
-
Azam M, Powers JT, Einhorn W, Huang WS, Shakespeare WC, Zhu X, Dalgarno D, Clackson T, Sawyer TK, and Daley GQ
- Subjects
- Adenine chemistry, Adenine pharmacology, Animals, Benzamides pharmacology, Binding Sites, Cell Line, Computer Simulation, Dasatinib, Fusion Proteins, bcr-abl genetics, Fusion Proteins, bcr-abl metabolism, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Mice, Mutation, Piperazines chemistry, Piperazines pharmacology, Protein Kinase Inhibitors pharmacology, Protein-Tyrosine Kinases genetics, Protein-Tyrosine Kinases metabolism, Pyrimidines chemistry, Pyrimidines pharmacology, Thiazoles chemistry, Thiazoles pharmacology, Adenine analogs & derivatives, Benzamides chemistry, Drug Resistance, Neoplasm, Fusion Proteins, bcr-abl antagonists & inhibitors, Protein Kinase Inhibitors chemistry, Protein-Tyrosine Kinases antagonists & inhibitors
- Abstract
Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance in patients with chronic myelogenous leukaemia. The second generation BCR/ABL inhibitors nilotinib and dasatinib effectively inhibit most imatinib resistance variants, but are ineffective against the gatekeeper mutant, T315I. Gatekeeper mutation activates the kinase by stabilizing the hydrophobic spine. Here, we describe that the rationally designed compound AP24163 can inhibit native and gatekeeper mutants of the BCR/ABL kinase. Structural modelling suggests that AP24163 affects the flexibility of the P-loop and destabilizes the active conformation by disrupting the hydrophobic spine. In vitro screening for drug resistance identified clones with compound mutations involving both the P-loop and T315I. Our studies provide structural insights for the design of inhibitors against the gatekeeper mutant and suggest that up-front combination therapy may be required to prevent the emergence of compound-resistant mutations.
- Published
- 2010
- Full Text
- View/download PDF